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RESPONDING to WOMEN’S NEEDS
Developing HIV and Multipurpose Prevention Products

2013 ANNUAL REPORT

Dear friends and colleagues,

Dr. Zeda F. Rosenberg
Chief Executive Officer

Dr. James McIntyre
Chair of the Board

Since our founding in 2002, the International Partnership for Microbicides (IPM) has dedicated itself to reducing the devastating toll
that HIV has taken on women by developing new products that would enable them to protect their sexual and reproductive health on
their own terms. Today, we are closer than ever to finding out whether the monthly dapivirine vaginal ring could be one such option.
Two Phase III trials of the ring, the IPM-led Ring Study and the Microbicide Trials Network (MTN)-led ASPIRE trial, are ongoing
at over 20 sites in Malawi, South Africa, Uganda and Zimbabwe. With these two studies running in parallel and with smaller
supporting studies of the ring, IPM has built a strong foundation from which to seek regulatory approval for the product should
the studies show safety and efficacy in 2016.
Pending results and regulatory approval, the ring could be available to women in sub-Saharan Africa as early as 2017. If the
results of the FACTS 001 trial expected early next year confirm the effectiveness of tenofovir gel, women could potentially benefit
from multiple products that meet their unique needs.
We recognize that HIV is but one among a constellation of threats to women’s sexual and reproductive health. IPM is actively developing new products in multiple formulations, including a 90-day vaginal ring that would protect women against both HIV and
unintended pregnancy. We anticipate that this multipurpose prevention technology (MPT) will enter Phase I trials in 2015. Given
our recently expanded partnership with Janssen R&D Ireland granting IPM exclusive worldwide rights to dapivirine, we could one
day make our MPT ring available to women everywhere.
Staying on the front lines of prevention science is critically important if we are to overcome the constantly changing HIV
epidemic. IPM is also pioneering the development of products that combine two types of antiretroviral drugs (ARVs) with different
mechanisms of action to help ensure that a next generation of products will be available to combat the epidemic in the future.
This work could not occur without the efforts of the women who volunteer for clinical trials, the support of communities where
the trials take place, research partners who conduct our trials, pharmaceutical companies who grant us licenses for their ARVs,
civil society groups that build political will for global health R&D, and our donors, whose investment in the promise of a world
where women can protect their own health renews our momentum every day. Each of these commitments sustains the research
that is responding to the most pressing sexual and reproductive health issues affecting women today.

Dr. Zeda F. Rosenberg

Dr. James McIntyre

Around the world, women face complex challenges to their sexual and reproductive health. Issues such as HIV and
unintended pregnancy have devastating effects on women, their families and their communities. IPM is designing a
product pipeline to overcome these challenges by using cutting-edge science to respond to the complexity of the HIV
epidemic and the diversity of individual needs. Here are five highlights from 2013:
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Dapivirine Ring: Progress on the Path to Licensure

Women of reproductive age are the most at-risk for HIV infection. In sub-Saharan Africa, where the epidemic has hit hardest
and is driven mainly by unprotected heterosexual sex, women
make up nearly 60 percent of HIV-positive adults. Globally,
young women ages 15-24 are twice as likely to be infected as
young men of the same age. Women urgently need new prevention options they can initiate themselves.
IPM’s discreet, easy-to-use monthly vaginal ring is designed to
protect women from HIV infection during sex. The long-acting
ring slowly releases an antiretroviral drug called dapivirine, a
non-nucleoside reverse transcriptase inhibitor, or NNRTI, that
prevents the virus from replicating in healthy cells. Because
women can insert the ring and leave it in place for one month,
it could help encourage consistent use.

Taking Phase III Trials to Scale
IPM brought the dapivirine ring from concept to Phase III

Supporting studies
In 2013, five smaller safety studies of the dapivirine ring were
conducted to support a robust data package for regulatory approval and eventual licensure. Studies that assessed interactions between dapivirine and a drug commonly used to treat
vaginal yeast infections, and the use of the ring with male
condoms both concluded in 2013. Results will be available in
2014. Studies initiated in 2013 are evaluating:
•
•
•

use of the ring with female condoms
extended use of the ring
safety of the ring in postmenopausal women over 45 		
(in partnership with MTN)

Studies planned for 2014 will assess:
•
•
•

effects of ring use during menses and with tampons
sociobehavioral factors of adherence
safety of the ring in adolescents (in partnership with MTN)

clinical trials in just seven years. To minimize the time between research and regulatory approval, which generally
requires replicated results from at least two late-stage trials,
IPM’s Dapivirine Ring Licensure Program includes two parallel Phase III trials. These two studies — The Ring Study, led
by IPM, and its sister study called ASPIRE, led by the MTN (a
National Institutes of Health-funded program),
together will determine the ring’s
efficacy and long-term safety. The Ring
Study and ASPIRE are the first Phase III
trials of a microbicide ring and expanded rapidly in 2013, with enrollment at
over 20 sites in Malawi, South Africa,
Uganda and Zimbabwe. The two studies
together are expected to include more
than 4,500 women volunteers ages
18-45, with results expected by 2016.
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You save a woman, you save a nation, you save the world.
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Clinical Trial Success Factors

Prioritizing Adherence
Previous IPM studies have found the ring technology to be
highly acceptable and well-tolerated by women and male
partners. Yet the success of any prevention product depends
on whether it is used consistently and correctly. HIV prevention
research has shown that ARV-based methods can be effective
when used as directed. That is why IPM focuses on promoting adherence in its clinical trials and identifying factors that
encourage adherence.
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How are we promoting adherence? IPM worked
closely with research centers in 2013 to offer
in-depth counseling training, refine adherence
messaging and plan local events that engage communities in supporting trial
participants to maintain adherence.

Shaping the HIV Prevention Landscape

Turning research into on-the-ground benefits for women is
a challenge for any organization. IPM is pursuing a comprehensive strategy to shorten the time line between clinical
trial results for the dapivirine ring and its potential licensure,
manufacturing and distribution.

Building a Case for Licensure
As the regulatory sponsor for the dapivirine ring, IPM continues to consult with regulatory authorities to understand
country dossier requirements, and help streamline the regulatory submission and approval process. IPM met with national
regulatory authorities in Kenya, Tanzania, Uganda, Zambia
and Zimbabwe in 2013 to discuss country-specific requirements. In 2014, IPM will continue to engage with regulatory
bodies in African countries where we hope the ring will be
made available, including the Medicines Control Council of
South Africa.
In addition, IPM has sought and received scientific advice
at every step in the process from the European Medicines
Agency (EMA), the US Food and Drug Administration (FDA)
and the Medical Products Agency in Sweden, where the ring
is manufactured. These consultations are key to expediting
future marketing approvals and review under EMA Article 58
and FDA, both of which which will inform the determination
of drug prequalification by the World Health Organization.
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How is adherence measured? The Ring Study and ASPIRE are
using objective methods to monitor participant adherence to
the monthly ring such as the amount of dapivirine remaining
in used rings as well as drug levels in plasma and vaginal fluid
samples. We are also collecting qualitative data from questionnaires and in-depth interviews.
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Assembling a Regulatory Dossier
To request regulatory approval for the dapivirine ring, IPM is building a dossier
of complete historical data on the product’s ingredients; data from over 200
chemistry, manufacturing and control, and preclinical studies; and results
from approximately 40 clinical studies. Because dapivirine is a new chemical
compound not yet reviewed by regulators, our data would serve as reference
for future dapivirine-based product submissions.

Moving Toward Access
IPM is leveraging its cross-sector collaborations and drawing
on lessons learned from the global health community’s experiences with product introduction in developing countries to
plan for providing the dapivirine ring to women most at risk of
HIV infection as quickly as possible upon regulatory approval.
In 2013, to prepare for the ring’s roll-out, IPM began identifying potential partners for the ring’s financing, commercial
manufacturing, distribution, marketing and health service use.
IPM will continue to refine its access strategy in consultation
with its donors and partners in 2014, including efforts to
minimize the costs of the dapivirine ring to governments and
end users, and to support country implementation through
possible small-scale demonstration projects and studies.

The success of The Ring Study would change lives!

– Dr. Sylvia Kusemererwa, Medical Research Council, Uganda

Fostering Local Research Capacity

Planning for Efficacy

In 2013, IPM worked closely with research center partners to
build skills and jointly develop solutions to potential challenges. IPM hosted trainings on topics such as good clinical
practices, data management and quality control, interview
techniques and study procedures. These ongoing collaborations help ensure the successful implementation of The Ring
Study and other microbicide trials, while helping to build
the capacity of the cadre of skilled African clinicians and
researchers who are committed to turning the tide of the
HIV epidemic.

Should both The Ring Study and ASPIRE show the dapivirine ring to be safe and effective in preventing HIV, IPM and
its partner MTN will invite former participants to enroll in
follow-on trials that provide early access to the dapivirine
ring. These Phase IIIb trials — now being designed — would
allow former Ring Study and ASPIRE participants who
remained HIV-negative to continue using the dapivirine ring
while regulatory approval is pending.
In 2014, IPM and MTN are meeting with civil society advocates to seek input on the designs of the two follow-on
studies in the four countries where the Phase III trials are now
under way. These meetings also examine the realities of HIV
prevention efforts on the ground and inform preparations for
future access to the ring.

Raising the Ring’s Profile Among
Health Workers
It is essential that health policymakers and health care providers —
who will have influence in determining the ring’s accessibility and
use — have a clear understanding of what microbicides are and the
role they can play in overall HIV prevention efforts. To this end, in 2013,
IPM embarked on a qualitative study of health workers’ knowledge
and perceptions of microbicides in Kenya, Malawi and Zimbabwe.
IPM is conducting in-depth interviews and focus group discussions
with health workers to assess knowledge gaps and factors that can
promote or slow the introduction of the dapivirine ring. In 2014, the
results will be used to inform the development and dissemination of
educational materials about microbicides in general and the dapivirine
ring specifically.
In 2013, IPM’s ring manufacturing partner, QPharma,
produced the thousands of rings needed to meet the demands
of both Phase III trials. Manufacturing for the Phase III trials and
supporting studies was recently completed.

Spotlight on Scale-up
In anticipation of the ring’s potential licensure, IPM is exploring various options that would enable higher product yields
and drive costs down. For example, increasing automation
and adding new equipment that would produce multiple
batches of rings simultaneously could save time and
translate to efficiencies of scale.

IPM: Do you have a
health worker photo
that you can send us
for here?
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Staying One Step Ahead of HIV

Microbicides will prevent HIV only if women use them in their
everyday lives. Women need multiple and complementary prevention tools that fit their needs — from oral ARVs to vaginal
rings and gels to a future vaccine and beyond. A diverse product pipeline, including products containing multiple classes
of ARVs that are used solely for HIV prevention, may increase
efficacy and help prevent the acquisition of drug-resistant HIV
over time.
Because it takes more than a decade for prevention technologies to go through clinical trials and reach regulatory approval,
research and development on additional drugs must happen
now. Through our six royalty-free licensing agreements with
pharmaceutical partners for eight different ARV compounds,
IPM is developing a range of products to address the urgent
health risks that women face every day.

Harnessing the Potential of Dapivirine
IPM’s first royalty-free licensing agreement was signed in 2004
with Janssen R&D Ireland, one of the Janssen Pharmaceutical
Companies of Johnson & Johnson, granting IPM the right
to develop dapivirine as a microbicide for use in developing
countries. This license has since been expanded to a worldwide
rights agreement. A highly potent NNRTI, dapivirine is not
used for treatment and has been shown to be safe and well-tolerated in all 26 clinical studies to date. Recognizing dapivirine’s
potential, IPM is also evaluating other dapivirine formulations
alone and with other ARVs.

A Multipurpose Prevention Ring for Broad
Sexual and Reproductive Health Needs
Given the dual threats women worldwide face from HIV and
unintended pregnancy, IPM is building on its ring technology with a long-acting multipurpose ring that contains both
dapivirine and the contraceptive levonorgestrel. Because many
women’s perceived risk of HIV is low compared to their perceived risk for pregnancy, combined technologies may one day
be more widely used than a product that targets HIV alone.
Protection for 90 days: In 2013, IPM worked with Particle Sciences, Inc. (US) and Queens University Belfast (QUB) (UK) to
design and evaluate several prototypes of this multipurpose
ring. IPM selected a silicone matrix formulation developed at
QUB that released the two drugs at stable levels over 90 days.
This long-acting feature would increase the ring’s convenience
and decrease its overall cost to women.
IPM is collaborating with QUB to develop the multipurpose
ring, which is anticipated to enter Phase I trials in 2015.
4
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Combination ARV Ring Shown to be Safe
Combining ARVs that use different mechanisms of action may
offer increased protection against HIV compared to a single
drug alone. In 2013, IPM’s dapivirine-maraviroc ring was found
to be safe, well-tolerated and acceptable in an MTN-led Phase I
trial — the first combination ARV microbicide to go to clinical trials. IPM is now optimizing the formulation to increase
maraviroc levels released from the ring over the course of
one month. The reformulated ring is expected to be ready for
preclinical testing in 2015.

Advancing Promising ARV Compounds
A potent gp120-binder licensed to IPM from Bristol-Myers
Squibb called DS003 presents a new mechanism of action that
has not yet been used in HIV prevention or treatment — greatly
increasing the chance it will be active against drug-resistant
HIV. Acting on that promise, IPM continued the development
of prototype DS003 vaginal tablets in 2013 and conducted
early preclinical assessments to help establish DS003’s safety
profile. Additional preclinical studies will be conducted in
2014. IPM is working to identify manufacturing partners for an
anticipated Phase I clinical trial in 2015. A ring formulation is
also being planned.

The Ring Study gives hope for women to have
peace of mind in preventing HIV/AIDS. We hope our
community will be among the first to start using the
ring when licensed.
– Rose Masilo, Madibeng Centre for Research, South Africa

Partnering for a Diverse Pipeline
Through collaborations with other product developers, IPM
leverages resources and scientific know-how to advance
IPM-licensed compounds and help expand the broader field’s
product pipeline.
IPM is providing clinical supplies and regulatory support to
collaborators to develop:
• Dapivirine vaginal film (NIH-funded Magee Womens
Research Institute FAME program), which was found to be
safe and acceptable in a 2013 Phase I safety study.
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Raising Microbicide Awareness

Community Engagement

Influencing Policy

Successful clinical research responds to the issues affecting
the communities in which it is conducted. IPM places a high
priority on community awareness and support, working with
research center partners to deliver educational materials and
hold local events and trainings. Strengthening research literacy in communities helps to increase awareness of HIV and
other health issues, a benefit that can continue long after
IPM’s studies have concluded.

IPM conducts outreach with national, regional and global
decision-makers who will have key roles in influencing future
access to microbicides and other tools women can use to
protect their health. In 2013, IPM worked with its network of
partners, including the Southern African AIDS Trust (SAT) and
Kenya Medical Women’s Association (KMWA), to offer research
briefings for policymakers and advocates that take into account the evolving political and social contexts that affect HIV
prevention and health care policy decisions. These coalitions
are critical to building the support needed to effectively deliver
new sexual and reproductive health products to the women
who need them most.

Scientific Leadership
In 2013, IPM continued to share its scientific research at several
major conferences, presenting on topics such as multipurpose
prevention ring development at the 2013 Women Deliver
Conference in Kuala Lumpur and at the annual Controlled
Release Society meeting in Hawaii, sociobehavioral aspects of
microbicide studies at the 11th International AIDSImpact
Conference in Barcelona, and clinical trial ethics at the 6th
annual South Africa AIDS Conference in Durban.

The South African National AIDS Council’s (SANAC) Women’s
Sector held its biennial Women’s HIV Prevention Summit in
September 2013. IPM supported the summit, which brought
together multiple sectors to focus on key issues in HIV
prevention among women.

• Maraviroc vaginal film (FAME program), plans for which
are under way.
• Maraviroc-based rectal gel (NIH-funded CHARM program
at the University of Pittsburgh), which showed protection
against HIV in a 2013 preclinical study in macaques.
A Phase I trial is planned for 2014.
• Dapivirine-darunavir ring and gel (European Commission-funded CHAARM consortium) was evaluated in preclinical studies in 2013, with a Phase I trial expected in 2014.

In addition, IPM’s published or supported work
appeared in a range of
peer-reviewed journals in
2013, including articles in
the Journal of the International AIDS Society on
participant adherence in
clinical trials and in Antiviral Research on the dapivirine ring’s development
and pharmacokinetics.

IPM led a panel on the role of global health
partnerships and presented on microbicides
and MPTs at the Women Deliver conference.

What gives me hope is knowing that we are working
toward a product — a microbicide for women — that
may help give women and their families a
better future.
– Dr. Cynthia Gama, Maternal, Adolescent and Child Health,
Wits University, South Africa

RESPONDING TO WOMEN’S NEEDS

5

IPM Donors

Board of Directors

Current Donors

James McIntyre, MBChB, Chair
Anova Health Institute, South Africa

Bill & Melinda Gates Foundation
Irish Aid, Department of Foreign Affairs
Ministry of Foreign Affairs of Denmark
Ministry of Foreign Affairs, the Netherlands
Norwegian Agency for Development
Cooperation
Norwegian Ministry of Foreign Affairs
OPEC Fund for International Development,
the development finance institution of
OPEC Member States
United Kingdom Department for International Development

Eunice Brookman-Amissah, MBChB
Ipas, Kenya
Bruce Burlington, MD
Independent Consultant, United States
Georgina Caswell, MA
International HIV/AIDS Alliance,
South Africa
Tamar Howson, MS, MBA
Independent Consultant, United States

United States Agency for International
Development through the United States
President’s Emergency Plan for AIDS Relief

Maureen Lewis, PhD
Georgetown University, United States
World Bank, United States

Previous Donors

Florence W. Manguyu, M.Med, MBChB
Aga Khan University Hospital; IAVI, Kenya

Ackerman Family Foundation
Belgian Development Cooperation
Canadian International Development
Agency
European Commission
Federal Ministry for Economic Cooperation
and Development, Germany
M•A•C AIDS Fund
Magee-Womens Research Institute and
Foundation

United Nations Population Fund
World Bank

Doug Taylor, PhD
FHI 360, United States
Jim A. Turpin, PhD
National Institute of Allergy and Infectious
Diseases, National Institutes of Health,
United States
Lut Van Damme, PhD
Bill & Melinda Gates Foundation,
United States

Robin Wood, PhD
Desmond Tutu HIV Centre, South Africa

Heidemarie Wieczorek-Zeul
German Bundestag, Germany

Robin Shattock, PhD, Chair
Imperial College London, United Kingdom

Unit4 Business Software

Deenan Pillay, MD
University College London School of Life
and Medical Sciences, United Kingdom

Michael Stevens
ENTHUSE Charitable Trust,
United Kingdom

Ministry of Foreign Affairs and
Cooperation, Spain

Swedish International Development
Agency

Derek Newall, PhD
GlaxoSmithKline, United Kingdom

Jens Van Roey, MD
Janssen Infectious Diseases - Diagnostics
BBVA, Belgium

Scientific Advisory Board

Rockefeller Foundation

Edith Nakku-Joloba, PhD
Makerere University, Uganda

Zeda F. Rosenberg, ScD
IPM, United States

Ministry for Foreign Affairs, Sweden

Ministry of Foreign Affairs, France

Thomas Moench, MD
ReProtect, Inc., United States

Michael Chirenje, MD
University of Zimbabwe, Zimbabwe
David R. Friend, PhD
CONRAD, United States
Sharon Hillier, PhD
Magee-Womens Hospital, University of
Pittsburgh School of Medicine,
United States
Ruth B. Merkatz, PhD, RN, FAAN
Population Council, United States

IPM Leadership
Zeda F. Rosenberg, ScD
Chief Executive Officer
Annalene Nel, MD, PhD
Executive Vice President, Chief Medical
Officer, Clinical Programs
Brid Devlin, PhD
Executive Vice President,
Product Development
Christopher Camut, MBA
Chief Financial Officer

2013 Financial Considerations
IPM’s cash, cash equivalents and short-term investments
as of December 31, 2013, were $38.2 million. During 2013,
IPM continued to increase clinical research center expenditures in Africa in support of The Ring Study, one of two
parallel Phase III clinical trials of the dapivirine ring. In
addition to the existing four research centers, IPM added
three new centers to support the ongoing clinical study.
In 2013, IPM received grant awards from: M•A•C AIDS
Fund (USD 50,000); Norwegian Agency for Development
Cooperation (NOK 20 million); OPEC Fund for International Development (USD 300,000); United Kingdom Department for International Development (GBP 15 million);
and United States Agency for International Development
through the United States President’s Emergency Plan for
AIDS Relief (two awards totaling USD 40 million). In addition, IPM continues to receive extraordinary support from
our other donors. IPM is in compliance with all financial

reporting requirements from all domestic and international government and private donors.
With new funding received in 2013, IPM also advanced
its product pipeline, an integral component of the organization’s strategy beyond our broader Dapivirine Ring
Licensure Program. IPM will continue to apply a highly
disciplined approach to product prioritization that advances only the most promising self-initiated HIV prevention
tools, and other sexual and reproductive health technologies for women.
IPM’s Board of Directors, management team and staff are
committed to capably delivering on our mission for women around the world, and for the donors whose support
fuels our progress. Sustained funding for IPM’s success
is essential, and we continue to advocate for increased
funds from existing donors and pursue new sources of
support to efficiently achieve our goals.

		

Assets

EXPENSES BY DEPARTMENT
Dec. 31, 2013

Cash and cash equivalents

$14,544,424

Investments, at market

$23,638,665

Accounts receivable

$182,413

Prepaid expenses and other current assets

$702,396

Property and equipment, net
Total Assets

$1,469,510
$40,537,408

External
Relations
8%

Institutional
Operating
19%
Clinical
Programs
37%

Liabilities and Net Assets
Liabilities
Accounts payable and accrued expenses

$4,396,442

Grant advances and deferred revenue

$19,024,833

Total Liabilities

$23,421,275

Net Assets - unrestricted

$17,116,133

Total Liabilities and Net Assets

$40,537,408

Regulatory
& Quality
Assurance
8%

Product
Development
28%

IPM Headquarters

IPM South Africa

8401 Colesville Road
Suite 200
Silver Spring, MD 20910 USA
Tel: +1-301-608-2221
Fax: +1-301-608-2241

63 Main Road
Paarl 7646, South Africa
P.O. Box 3460
Tel: +27-21-860-2300
Fax: +27-21-860-3208/1000

Learn more about how to promote
women’s health worldwide and
save millions of lives at

www.IPMglobal.org

